Citations

Showing 10 of 108094 citations.

A roadmap for clinical trial design in marginal zone lymphoma
Alderuccio, Juan Pablo , Habermann, Thomas M. , Kuker, Russ , Moskowitz, Craig H. , Lossos, Izidore S. , Habermann, Thomas , Lossos, Izidore S , Zelenetz, Andrew D.

Mayo Clinic

American Journal of Hematology | August 28, 2022 | Volume: 97 | Issue: 11 | Pages: 1398-1403

10.1002/ajh.26706 | PMID 36030403 Get It

The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy
Bhutani, Gauri , Leung, Nelson , Said, Samar M. , Valeri, Anthony M., Fidler, Mary E., Alexander, Mariam P., Cornell, Lynn D. , Nasr, Samih H. , Leung, Nelson , Cornell, Lynn , Astor, Brad C.

Mayo Clinic

American Journal of Hematology | August 28, 2022 | Volume: 97 | Issue: 11 | Pages: No page available

10.1002/ajh.26705 | PMID 36054780 Get It

Glioblastoma, IDH-Wildtype Harboring a KIAA1549::BRAF Fusion: Report of a Case With Comprehensive Molecular Profiling
Berry, John F. , Vidrine, Devan W. , Wojcik, Antonina A, Trivedi, Darshan, Quezado, Martha , Abdullaev, Zied , Ketchum, Courtney , Aldape, Kenneth , Jenkins, Robert B. , Aldape, Kenneth , Jenkins, Robert, Ida, Cristiane M , Wojcik, Antonina A., Keen, Joseph, Pratt, Drew , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | August 27, 2022 | Volume: 81 | Issue: 12 | Pages: 1026-1028

10.1093/jnen/nlac076 | PMID 36029520 Get It

Critical Care Cardiology Trials Network (CCCTN): a cohort profile
Metkus, Thomas S. , Baird-Zars, Vivian M., Alfonso, Carlos E., Alviar, Carlos L. , Barsness, Gregory W. , Bertić, Mia , Bohula, Erin A. , Burke, James A. , Burstein, Barry , Cooper, Howard A., Daniels, Lori B. , Goldfarb, Michael , Katz, Jason N. , Keeley, Ellen C. , Keller, Norma, Kenigsberg, Benjamin B. , Kontos, Michael C. , Lawler, Patrick R. , Leibner, Evan , Menon, Venu , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Papolos, Alexander , Pierce, Matthew J, Prasad, Rajnish, Pisani, Barbara , Smith, Timothy D., Snell, R. Jeffrey, So, Derek , Ternus, Bradley , Teuteberg, Jeffrey J. , Zakaria, Sammy , Goldfarb, Michael , Pierce, Matthew , Fordyce, Christopher B , Goldfarb, Michael , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Lawler, Patrick , Daniels, Lori B , Bohula, Erin A , Zakaria, Sammy , O'Brien, Connor G , Pierce, Matthew J , Barnett, Christopher F. , Berg, David D. , Burke, James, Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Kwon, Younghoon, Liu, Shuangbo , Prasad, Rajnish, Potter, Brian J , Roswell, Robert O. , Sinha, Shashank S , Shah, Kevin S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 27, 2022 | Volume: 8 | Issue: 7 | Pages: 703-708

10.1093/ehjqcco/qcac055 | PMID 36029517 Get It

AbstractAimsThe aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness.Methods and resultsThe CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness.ConclusionThe CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D’Souza, Anita , Shah, Nina , Rodriguez, Cesar, Voorhees, Peter M. , Bueno, Orlando F. , Pothacamury, Rajvineeth Kumar, Freise, Kevin J. , Yue, Susan, Ross, Jeremy A. , Polepally, Akshanth R. , Talati, Chetasi, Buelow, Ben , Vij, Ravi , Kumar, Shaji , Polepally, Akshanth R , Buelow, Ben , Vij, Ravi , Kumar, Shaji K , D'Souza, Anita , Voorhees, Peter , Weisel, Katja C , Talati, Chetasi , Lee, Shane , Jin, Ziyi

Mayo Clinic

Journal of Clinical Oncology | August 27, 2022 | Volume: 40 | Issue: 31 | Pages: 3576-3586

10.1200/jco.22.01504 | PMID 36029527 Get It

PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study. METHODS Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion. RESULTS As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively. CONCLUSION ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.
Physical activity and the risk of non‐Hodgkin lymphoma subtypes: A pooled analysis
Boyle, Terry , Kleinstern, Geffen , Bracci, Paige M. , Cerhan, James R. , Benavente, Yolanda , Casabonne, Delphine , Holly, Elizabeth A., Liebow, Mark , Paltiel, Ora , Robinson, Dennis P. , Rothman, Nathaniel , Wang, Sophia , Weisenburger, Dennis D. , Spinelli, John J., Norman, Aaron, Paltiel, Ora , Robinson, Dennis, Rothman, Nathaniel , Cerhan, James R , Wang, Sophia S , Chiu, Brian C.‐H. , Habermann, Thomas M. , Norman, Aaron D. , Rothman, Nathaniel , Seir, Rania Abu , Slager, Susan L. , Villeneuve, Paul J.

Mayo Clinic

International Journal of Cancer | August 27, 2022 | Volume: 152 | Issue: 3 | Pages: 396-407

10.1002/ijc.34266 | PMID 36054546 Get It

AbstractNon‐Hodgkin lymphoma (NHL) is composed of a heterogeneous collection of subtypes with considerable differences in genetics, biology and aetiology. Studies to date on physical activity and NHL risk have not had sufficient sample size to evaluate whether associations differ by subtype. We pooled data from nine case‐control studies to examine the association between moderate‐to‐vigorous intensity physical activity (MVPA) and risk of NHL overall and by subtype (diffuse large B‐cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, marginal zone lymphoma and mature T‐cell lymphoma). A total of 5653 cases and 9115 controls were included in the pooled analysis. Physical activity was harmonised across nine studies and modelled as study‐specific tertiles. Multinomial logistic regression was used to estimate the association between physical activity and NHL, adjusting for confounders. The overall odds of NHL was 13% lower among participants in the most active tertile of MVPA compared to the least active tertile (adjusted odds ratio = 0.87, 95% CI = 0.80, 0.95). Similar decreases were observed across NHL subtypes. In summary, in this pooled analysis of case‐control studies, physical activity was associated with a modest risk reduction for each NHL subtype examined and with overall NHL.
Pearls & Oy-sters: Postpipeline Headache Phenomenon
Ighodaro, Eseosa T. , Ghislain, Brandon, Scharf, Eugene , Robertson, Carrie E. , Scharf, Eugene L , Robertson, Carrie E , Robertson, Carrie E

Mayo Clinic

Neurology | August 26, 2022 | Volume: 99 | Issue: 16 | Pages: 718-720

10.1212/wnl.0000000000201157 | PMID 36028323 Get It

Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials
Meschia, James F. , Brott, Thomas G. , Voeks, Jenifer H. , Howard, Virginia J. , Voeks, Jenifer , Meschia, James F , Howard, Virginia J , Howard, George

Mayo Clinic

Neurology | August 26, 2022 | Volume: 99 | Issue: 21 | Pages: No page available

10.1212/wnl.0000000000201188 | PMID 36028326 Get It